UPDATE: Sarepta Downgraded by Citigroup on Eteplirsen Early Approval Setback

Loading...
Loading...
In a report published Monday, Citigroup analysts Yaron Werber and Jonathan Eckard downgraded
Sarepta TherapeuticsSRPT
from a NEUTRAL to SELL, adjusting the price target to $13. The Citigroup analysts noted, “..we do not anticipate that FDA will reverse its view that eteplirsen's ph 2 data is not sufficient to file. We expect eteplirsen's approval will be delayed until at least ‘17. We view the path ahead as being risky, lengthy and expensive and the recent strong stock rebound on hopes for early filing is overdone.” SRPT closed previously on Friday at $20.44 and is currently trading around $18.02.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: DowngradesPrice TargetAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...